New York — Caris Life Sciences, a life sciences company, announced on Monday that it has completed a $168 million financing round aimed at supporting the expansion plans for its genomic profiling platform. The round was led by existing investor Braidwell, with new investors including Perceptive Advisors, Woodline, and Ghisallo, while existing investors Millennium Management and First Light Asset Management also participated in the follow-on investment.Caris Life Sciences CEO David Halbert stated, "This financing will enable us to bring our leading scientific technologies to more patients and further advance the transformative goal of precision medicine. We plan to fully unlock the potential of precision medicine by comprehensively deciphering cancer at the molecular level, driving revolutionary applications of molecular science."Currently, Caris Life Sciences' core products include the recently launched MI Cancer Seek — a test method based on whole-exome and whole-transcriptome sequencing (WES/WTS) with FDA-approved companion diagnostic indications — and the **Caris Assure** test for liquid biopsy treatment selection. These technologies aim to provide personalized diagnosis and treatment plans for cancer patients through multi-omics analysis.Investors Are Optimistic About the Future of Precision MedicineRepresentatives of the new investor, Perceptive Advisors, noted: "Caris' innovative capabilities and data accumulation in the field of molecular diagnostics are impressive, and its platform has the potential to redefine the standard for precision in cancer treatment." Existing investor Braidwell emphasized that Caris' technology integration and commercialization capabilities were key reasons for continued investment.Industry Impact and Future LayoutCaris Plans to Use the Funds to Expand Its Global Laboratory Network, Enhance AI-Driven Data Analysis Capabilities, and Accelerate the Development of Novel Companion Diagnostic Tools. With the Growing Demand for Precision Medicine, Caris' Financing is Expected to Further Solidify Its Leading Position in the Field of Oncology Molecular Testing.About Caris Life SciencesCaris Life Sciences, headquartered in Texas, USA, focuses on advancing precision cancer diagnosis and treatment through multi-omics technologies (including genomic, transcriptomic, and proteomic analyses). Its database covers more than 500,000 tumor samples, providing critical support for clinical research and drug development.Source: Read Creation Finance, Snowball, Announcement, Medical Industry Observer
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)